Ezh2 inhibitor combination therapies
AssigneePfizer Inc.
InventorsManfred Kraus, Pei-Pei Kung, Thomas Andrew Paul, Shikhar Sharma, Dominique Verhelle
Life of this patent
Estimating the term…
Abstract
This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.
Claims31
A method of treating cancer in a subject comprising administering to the subject a combination therapy which comprises an EZH2 inhibitor, or a pharmaceutically acceptable salt thereof, and a platinum based antineoplastic agent, or a pharmaceutically acceptable salt thereof.
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising an EZH2 inhibitor, or a pharmaceutically acceptable salt thereof, and a platinum based anti-neoplastic agent, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A kit which comprises a first container, a second container and a package insert, wherein the first container comprises at least one dose of an EZH2 inhibitor, or a pharmaceutically acceptable salt thereof, the second container comprises at least one dose of a platinum based anti-neoplastic agent, or a pharmaceutically acceptable salt thereof, and the package insert comprises instructions for treating a subject for cancer using the medicaments.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.